Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tectonic Therapeutic Inc.
Headquarters: Allston, MA, United States of America
Website: https://tectonictx.com/
Year Founded: 2020
Status: Public
Industry Sector: CommercialServices
CEO: Alise S. Reicin, MD
Number Of Employees: 13
Enterprise Value: $-36,812,520
PE Ratio: -2.42
Exchange/Ticker 1: NASDAQ:TECX
Exchange/Ticker 2: N/A
Latest Market Cap: $433,576,096
BioCentury | Feb 7, 2025
Finance
Strong demand for Sionna latest good sign for IPOs: Public Equity Report
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
BioCentury | Feb 6, 2025
Product Development
Cardiometabolic wins among highlights in BioCentury’s latest Clinical Report
Plus readouts from Allakos, Leap, Cargo and more
BioCentury | Jun 26, 2024
Management Tracks
Arvinas, Frontier name new CFOs
Plus: Audrey Duval to lead corporate affairs at Sanofi, and updates from MOMA,
BioCentury | Jun 21, 2024
Finance
Public Equity Report: Cinclus dips after pricing Stockholm IPO
Plus: Tectonic arrives on NASDAQ; UroGen prices offering amid rolling NMIBC submission
BioCentury | Jun 5, 2024
Management Tracks
Holt resignation leaves Amarin with third CEO in 14 months
Plus: FNIH awards Lurie Prize to Stanford’s Chang, and updates from Tectonic and Contineum
BioCentury | Mar 20, 2024
Product Development
Non-profit biotech aims to revive stalled ultrarare therapies
Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model
BioCentury | Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
BioCentury | Feb 2, 2024
Finance
Public equity roundup: Alto, Fractyl price IPOs, Vaxcyte raises $750M
Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus
BioCentury | Jul 20, 2022
Management Tracks
Gur, Clifford to lead U.K.’s new Advanced Research and Invention Agency
Plus restructuring at Invitae brings new CEO, and updates from Codexis, Compass, Tectonic and more
BioCentury | Jul 23, 2021
Management Tracks
Frazier joins General Catalyst as executive chairman of Health Assurance Initiatives
Plus: GSK, Quell, Tectonic, Coherus and more
Items per page:
1 - 10 of 13